Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1913 9
1914 2
1915 5
1917 1
1918 2
1919 6
1920 4
1921 2
1922 1
1923 2
1924 4
1925 1
1926 2
1930 1
1931 2
1932 5
1933 3
1934 1
1935 1
1953 1
1954 1
1955 1
1961 3
1962 2
1963 1
1965 2
1966 6
1967 4
1968 2
1969 3
1970 4
1971 3
1972 6
1973 2
1974 2
1975 6
1976 4
1977 4
1978 4
1979 5
1980 3
1981 10
1982 6
1983 5
1984 5
1985 4
1986 1
1987 3
1988 3
1989 4
1990 7
1991 5
1992 5
1993 9
1994 6
1995 9
1996 11
1997 6
1998 4
1999 5
2000 1
2001 2
2002 6
2003 1
2004 9
2005 11
2006 10
2007 10
2008 11
2009 9
2010 15
2011 15
2012 16
2013 18
2014 18
2015 23
2016 17
2017 18
2018 17
2019 19
2020 29
2021 16
2022 25
2023 22
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

536 results

Results by year

Filters applied: . Clear all
Page 1
Mitochondrial Stress Response and Cancer.
O'Malley J, Kumar R, Inigo J, Yadava N, Chandra D. O'Malley J, et al. Trends Cancer. 2020 Aug;6(8):688-701. doi: 10.1016/j.trecan.2020.04.009. Epub 2020 May 22. Trends Cancer. 2020. PMID: 32451306 Free PMC article. Review.
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Soong W, Gonzalez ME, Schneider LC, Sidbury R, Lockshin B, Meltzer S, Wang Z, Mannent LP, Amin N, Sun Y, Laws E, Akinlade B, Dillon M, Kosloski MP, Kamal MA, Dubost-Brama A, Patel N, Weinreich DM, Yancopoulos GD, O'Malley JT, Bansal A; participating investigators. Paller AS, et al. Among authors: o malley jt. Lancet. 2022 Sep 17;400(10356):908-919. doi: 10.1016/S0140-6736(22)01539-2. Lancet. 2022. PMID: 36116481 Clinical Trial.
Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.
Yosipovitch G, Mollanazar N, Ständer S, Kwatra SG, Kim BS, Laws E, Mannent LP, Amin N, Akinlade B, Staudinger HW, Patel N, Yancopoulos GD, Weinreich DM, Wang S, Shi G, Bansal A, O'Malley JT. Yosipovitch G, et al. Among authors: o malley jt. Nat Med. 2023 May;29(5):1180-1190. doi: 10.1038/s41591-023-02320-9. Epub 2023 May 4. Nat Med. 2023. PMID: 37142763 Free PMC article. Clinical Trial.
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.
Paller AS, Siegfried EC, Thaçi D, Wollenberg A, Cork MJ, Arkwright PD, Gooderham M, Beck LA, Boguniewicz M, Sher L, Weisman J, O'Malley JT, Patel N, Hardin M, Graham NMH, Ruddy M, Sun X, Davis JD, Kamal MA, Khokhar FA, Weinreich DM, Yancopoulos GD, Beazley B, Bansal A, Shumel B. Paller AS, et al. Among authors: o malley jt. J Am Acad Dermatol. 2020 Nov;83(5):1282-1293. doi: 10.1016/j.jaad.2020.06.054. Epub 2020 Jun 20. J Am Acad Dermatol. 2020. PMID: 32574587 Free article. Clinical Trial.
Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial.
Weidinger S, Bieber T, Cork MJ, Reich A, Wilson R, Quaratino S, Stebegg M, Brennan N, Gilbert S, O'Malley JT, Porter-Brown B. Weidinger S, et al. Among authors: o malley jt. Br J Dermatol. 2023 Oct 25;189(5):531-539. doi: 10.1093/bjd/ljad240. Br J Dermatol. 2023. PMID: 37463508 Free article. Clinical Trial.
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA, Deleuran M, Bissonnette R, de Bruin-Weller M, Galus R, Nakahara T, Seo SJ, Khokhar FA, Vakil J, Xiao J, Marco AR, Levit NA, O'Malley JT, Shabbir A. Beck LA, et al. Among authors: o malley jt. Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3. Am J Clin Dermatol. 2022. PMID: 35503163 Free PMC article.
Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism.
Pan Y, Tian T, Park CO, Lofftus SY, Mei S, Liu X, Luo C, O'Malley JT, Gehad A, Teague JE, Divito SJ, Fuhlbrigge R, Puigserver P, Krueger JG, Hotamisligil GS, Clark RA, Kupper TS. Pan Y, et al. Among authors: o malley jt. Nature. 2017 Mar 9;543(7644):252-256. doi: 10.1038/nature21379. Epub 2017 Feb 20. Nature. 2017. PMID: 28219080 Free PMC article.
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, Browning J, Soong W, Sun X, Chen Z, Kosloski MP, Kamal MA, Delevry D, Chuang CC, O'Malley JT, Bansal A. Blauvelt A, et al. Among authors: o malley jt. Am J Clin Dermatol. 2022 May;23(3):365-383. doi: 10.1007/s40257-022-00683-2. Epub 2022 May 14. Am J Clin Dermatol. 2022. PMID: 35567671 Free PMC article. Clinical Trial.
536 results